Hansa Biopharma AB
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Hansa Biopharma AB
Hansa Biopharma AB is a biopharmaceutical company that develops immunomodulatory treatments for enabling transplantations and rare immunoglobulin G (IgG)-mediated autoimmune conditions, transplant rejection, and cancer. The company's product candidate, imlifidase, is an antibody-cleaving enzyme being developed to enable kidney transplantation in sensitized patients and further developed for use in other organ and tissue transplantation as well as acute autoimmune indications. It operates in Sweden, other European countries, and the U.S. The group generates the majority of its revenue from product sales.
/ 
Others were interested in
Frequently asked questions
To buy Hansa Biopharma AB stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Hansa Biopharma AB by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Hansa Biopharma AB is HNSA:xome. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Hansa Biopharma AB has its primary listing on NASDAQ OMX Stockholm. You can trade Hansa Biopharma AB with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Hansa Biopharma AB is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Hansa Biopharma AB as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures—so you can make more informed decisions when considering shares like Hansa Biopharma AB.